Quality of life and severity of skin changes in the dynamics of psoriasis

Owczarek, Krzysztof; Jaworski, Mariusz

doi:10.5114/pdia.2015.54873

Cited by 25 publications

(27 citation statements)

References 29 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Poor quality of life, stigmatization and dissatisfaction with the treatment of psoriasis often result in insufficient patient cooperation and compliance, followed by inappropriate treatment procedures and lower treatment efficiency. This results in a patient's compromised well-being, and thus a vicious circle is formed (30). When the depression symptoms are reduced, manifestations of psoriasis reduce as well, and the patients' quality of life improves.…”

Section: Organization Of Research Of the Basic Setmentioning

confidence: 99%

Psoriasis – the impact on an individual´s mental state and quality of life

Vévodová¹,

Havelka

Vévoda³

et al. 2019

J. appl. health sci. (Online)

View full text Add to dashboard Cite

Introduction: Psoriasis is a chronic skin disease characterized by scaly patches affecting approximately 2-5% of the population. The disease has a negative impact on quality of life and, therefore, psoriatic patients often develop depression. Our work deals with quality of life and depression in psoriasis sufferrers and strives to determine the correlation between their quality of life and depression. Methods: The research took place in the University Hospital Olomouc in 2017 and used questionnaires WHOQOL-BREF and BDI-II. 50 patients with psoriasis were chosen randomly. To process the data we used Mann-Whitney test (the level of significance = 5%) and Spearman´s correlation coefficient (the level of significance = 1%). Results: The results proved that psoriasis has a significant impact on quality of life. The scores for the overall life quality as well as for individual domains were significantly lower in psoriatic patients than in the control group (p<0.001). The degree of depression in patients with psoriasis showed statistically significant correlation in all domains of the quality of life. We proved negative correlation in the overall quality of life (rs =- 0.691**), physical condition (rs =-0.499**), social relations (rs =-0.546**), overall health (rs =-0.396**), and environment (rs =-0.386**). Conclusion: With regard to the ascertained negative correlation between psoriasis and depression and lower quality of life of the sufferers compared to the healthy population, it is essential for healthcare professionals to pay attention not only to somatic manifestations of the disease but also to the patients´ mental health.

show abstract

Section: Organization Of Research Of the Basic Setmentioning

confidence: 99%

Psoriasis – the impact on an individual´s mental state and quality of life

Vévodová¹,

Havelka

Vévoda³

et al. 2019

J. appl. health sci. (Online)

View full text Add to dashboard Cite

show abstract

“…Psoriasis is a systemic, chronic, immune‐mediated disease of the skin that can have a significant impact on patients’ quality of life, especially for those with moderate to severe disease . Psoriasis is prevalent worldwide and has geographical and racial variation.…”

Section: Introductionmentioning

confidence: 99%

“…Psoriasis is a systemic, chronic, immune-mediated disease of the skin that can have a significant impact on patients' quality of life, especially for those with moderate to severe disease. [1][2][3] Psoriasis is prevalent worldwide and has geographical and racial variation. Psoriasis affects 2%-4% of the population in the USA and Europe, but has a lower prevalence in Asian countries (0.3% in China, 0.19%-0.24% in Taiwan, 0.44%-0.45% in Korea and 0.34% in Japan).…”

Section: Introductionmentioning

confidence: 99%

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study

Lee

Huang

Lee

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

The 52‐week results from the CLEAR (NCT02074982) study showed high and superior efficacy of secukinumab versus ustekinumab in clearing skin and improving patient‐reported outcomes, with comparable safety profile in subjects with moderate to severe psoriasis. Here, we analyzed the efficacy and safety of secukinumab in Asian subjects from the CLEAR study. In this double‐blind, phase IIIb study, eligible subjects with moderate to severe plaque psoriasis were randomized (1:1) to receive s.c. injection of secukinumab 300 mg or ustekinumab as per label. Of 62 subjects included in Asian subanalyses, 23 were randomized to secukinumab and 39 to ustekinumab. A significantly higher proportion of subjects achieved 90% or more improvement in Psoriasis Area and Severity Index (PASI 90) with secukinumab versus ustekinumab at week 16 (78.3% vs 35.9%, P = 0.0010) and at week 52 (60.9% vs 33.3%, P = 0.0196). Similarly, a higher proportion of subjects achieved PASI 100 with secukinumab versus ustekinumab at week 16 (43.5% vs 10.3%, P = 0.0029) and at week 52 (30.4% vs 12.8%, P = 0.0704). The median time to achieve 50% improvement in baseline PASI was 2.8 weeks in the secukinumab group versus 6.3 weeks in the ustekinumab group. The safety profile of secukinumab was in line with the known profile and no deaths occurred. Overall, 95.7% and 84.6% of subjects remained on secukinumab and ustekinumab, respectively. Similar to the core study, secukinumab showed sustained and superior efficacy with faster response versus ustekinumab, and no new or unexpected safety concerns were identified, in Asian subjects with moderate to severe plaque psoriasis.

show abstract

“…The incidence of mood disorders like depression and anxiety in those patients is higher than in general population. The quality of life is also significantly impaired due to the constant need of treatment, hospitalizations, missed work days, itching and interference with daily activities, among others [6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Biological therapies in psoriasis - revisited

Sârbu

Georgescu

Tampa

et al. 2018

Romanian Journal of Internal Medicine

View full text Add to dashboard Cite

Psoriasis is a chronic, immune mediated disorder affecting approximately 2% of the population. Even in our days, patients with psoriasis are confronted with stigmatization and social rejection. As a result, their quality of life is significantly impaired. Biological therapies have revolutionized the treatment of moderate to severe psoriasis. The aim of this paper is to look over the most important biological therapies available for the management of plaque-type psoriasis.

show abstract

Quality of life and severity of skin changes in the dynamics of psoriasis

Cited by 25 publications

References 29 publications

Psoriasis – the impact on an individual´s mental state and quality of life

Psoriasis – the impact on an individual´s mental state and quality of life

Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study

Biological therapies in psoriasis - revisited

Contact Info

Product

Resources

About